Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 13.01
- Piotroski Score 1.00
- Grade Buy
- Symbol (MLYS)
- Company Mineralys Therapeutics, Inc.
- Price $13.49
- Changes Percentage (-0.07%)
- Change -$0.01
- Day Low $13.35
- Day High $13.70
- Year High $16.91
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $30.00
- Low Stock Price Target $30.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.18
- Trailing P/E Ratio -6.03
- Forward P/E Ratio -6.03
- P/E Growth -6.03
- Net Income $-71,898,000
Income Statement
Quarterly
Annual
Latest News of MLYS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Even with losses, shareholders can profit by investing in a good business at the right price. Mineralys Therapeutics (NASDAQ:MLYS) has a solid cash runway but increasing cash burn. Shareholders should...
By Yahoo! Finance | 2 weeks ago -
Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares
On July 11, 2024, Adam Levy, CFO of Mineralys Therapeutics Inc (NASDAQ:MLYS), sold 10,757 shares at $13.14 each, now holding 247,611 shares. The company focuses on precision medicine for cardiovascula...
By Yahoo! Finance | 3 months ago -
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares
Mineralys Therapeutics Inc focuses on developing therapies for cardiovascular and cardiorenal diseases. Recent insider transactions, including significant share sales by Jon Congleton, have drawn atte...
By Yahoo! Finance | 3 months ago
